- Home
- ZBRA vs ILMN Comparison
ZBRA vs ILMN Comparison
Compare ZBRA & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBRA
- ILMN
- Stock Information
- Founded
- ZBRA 1969
- ILMN 1998
- Country
- ZBRA United States
- ILMN United States
- Employees
- ZBRA N/A
- ILMN N/A
- Industry
- ZBRA Industrial Machinery/Components
- ILMN Medical Specialities
- Sector
- ZBRA Industrials
- ILMN Health Care
- Exchange
- ZBRA Nasdaq
- ILMN Nasdaq
- Market Cap
- ZBRA 21.1B
- ILMN 23.6B
- IPO Year
- ZBRA 1991
- ILMN 2000
- Fundamental
- Price
- ZBRA $383.47
- ILMN $134.03
- Analyst Decision
- ZBRA Buy
- ILMN Buy
- Analyst Count
- ZBRA 10
- ILMN 19
- Target Price
- ZBRA $398.40
- ILMN $162.67
- AVG Volume (30 Days)
- ZBRA 304.7K
- ILMN 1.8M
- Earning Date
- ZBRA 02-13-2025
- ILMN 02-06-2025
- Dividend Yield
- ZBRA N/A
- ILMN N/A
- EPS Growth
- ZBRA N/A
- ILMN N/A
- EPS
- ZBRA 7.36
- ILMN N/A
- Revenue
- ZBRA $4,656,000,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- ZBRA $10.47
- ILMN N/A
- Revenue Next Year
- ZBRA $8.02
- ILMN $4.28
- P/E Ratio
- ZBRA $53.64
- ILMN N/A
- Revenue Growth
- ZBRA N/A
- ILMN N/A
- 52 Week Low
- ZBRA $233.95
- ILMN $97.36
- 52 Week High
- ZBRA $413.44
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- ZBRA 39.34
- ILMN 37.76
- Support Level
- ZBRA $401.55
- ILMN $140.29
- Resistance Level
- ZBRA $411.34
- ILMN $148.51
- Average True Range (ATR)
- ZBRA 7.93
- ILMN 5.52
- MACD
- ZBRA -2.93
- ILMN -0.58
- Stochastic Oscillator
- ZBRA 3.29
- ILMN 4.47
About ZBRA Zebra Technologies Corporation
Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.